Last reviewed · How we verify
Crenezumab dose level 1
Crenezumab dose level 1 is a Small molecule drug developed by Genentech, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Crenezumab dose level 1 |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease (PHASE1)
- A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crenezumab dose level 1 CI brief — competitive landscape report
- Crenezumab dose level 1 updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI
Frequently asked questions about Crenezumab dose level 1
What is Crenezumab dose level 1?
Crenezumab dose level 1 is a Small molecule drug developed by Genentech, Inc..
Who makes Crenezumab dose level 1?
Crenezumab dose level 1 is developed by Genentech, Inc. (see full Genentech, Inc. pipeline at /company/genentech-inc).
What development phase is Crenezumab dose level 1 in?
Crenezumab dose level 1 is in Phase 1.
Related
- Manufacturer: Genentech, Inc. — full pipeline
- Compare: Crenezumab dose level 1 vs similar drugs
- Pricing: Crenezumab dose level 1 cost, discount & access